Gandara David R, Hammerman Peter S, Sos Martin L, Lara Primo N, Hirsch Fred R
Davis Comprehensive Cancer Center, University of California, Sacramento, California.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Clin Cancer Res. 2015 May 15;21(10):2236-43. doi: 10.1158/1078-0432.CCR-14-3039.
Squamous cell lung cancer (SCC) represents an area of unmet need in lung cancer research. For the past several years, therapeutic progress in SCC has lagged behind the now more common non-small cell lung cancer histologic subtype of adenocarcinoma. However, recent efforts to define the complex biology underlying SCC have begun to bear fruit in a multitude of ways, including characterization of previously unknown genomic and signaling pathways, delineation of new, potentially actionable molecular targets, and subsequent development of a large number of agents directed against unique SCC-associated molecular abnormalities. For the first time, SCC-specific prognostic gene signatures and predictive biomarkers of new therapeutic agents are emerging. In addition, recent and ongoing clinical trials, including the Lung-MAP master protocol, have been designed to facilitate approval of targeted therapy-biomarker combinations. In this comprehensive review, we describe the current status of SCC therapeutics, recent advances in the understanding of SCC biology and prognostic gene signatures, and the development of innovative new clinical trials, all of which offer new hope for patients with advanced SCC.
肺鳞状细胞癌（SCC）是肺癌研究中尚未满足需求的领域。在过去几年中，SCC的治疗进展落后于目前更为常见的非小细胞肺癌组织学亚型腺癌。然而，最近为定义SCC潜在的复杂生物学机制所做的努力已开始在诸多方面取得成果，包括对先前未知的基因组和信号通路的表征、对新的、可能具有可操作性的分子靶点的描绘，以及随后针对独特的SCC相关分子异常开发大量药物。首次出现了SCC特异性预后基因特征和新型治疗药物的预测生物标志物。此外，近期及正在进行的临床试验，包括Lung - MAP主方案，旨在促进靶向治疗 - 生物标志物组合的获批。在这篇全面综述中，我们描述了SCC治疗的现状、对SCC生物学和预后基因特征理解的最新进展，以及创新性新临床试验的开展，所有这些都为晚期SCC患者带来了新希望。
